Sequential therapy with @entity1206 followed by XXXX in @entity1 with metastatic @entity1149 ( @entity1149 ), @entity13770 or elderly with comorbidities: A multicenter phase II trial.

@entity1 @entity13770 @entity137 @entity66 @entity16 @entity1149 @entity1295 @entity448 @entity1206 @entity74 @entity13769 @entity1431 @entity136
UNASSIGNED: 7119 Background: @entity1206 (V) and @entity136 (G) are active, well tolerated agents in @entity1149 . They have different mechanisms of action and are easily administered on an outpatient basis. METHODS: Forty-four @entity1 (pts), 42 evaluable, were entered between August 2001 and May 2003. They received V 30 mg/m2 i.v. on Days 1 and 8 every three weeks, two cycles for @entity66 ( @entity66 ) or one (1) cycle after best response (BR) followed by G 1000 mg/m2 i.v. on Days 1 and 8 every three weeks, two cycles for @entity66 or one cycle after BR. Then stable pts continued until @entity74 ( @entity74 ) on V or G according to pts' preference. Thirty seven pts had stage IV and five pts stage IIIB disease, 32 males, 10 females, median age 75, 21 pts with ECOG @entity13770 , 17 pts with ECOG @entity13769 , and 4 pts with ECOG PS 0. Pts' comorbidities were cardiovascular, pulmonary, or neurological. RESULTS: A total of 124 cycles of V were administered, median of 3 cycles per pt and 69 cycles of G, median of 1 cycle per pt. Sixteen pts (38 %) achieved partial response (PR), 11 pts on V and 5 pts on G, eleven pts (26.7 %) had @entity66 , 7 pts on V and 4 pts on G. Of 24 pts with @entity74 on V, three pts (12.5 %) responded to G. Median time to first @entity74 was 3.5 months. Median survival has surpassed six months and eight pts (19 %) already survived over one year. Thirteen pts are still alive after six months of minimal follow-up. @entity137 was minimal, six pts had grade 2 @entity1431 , two pts received red cell transfusions, no grade 3 or 4 @entity137 were reported. Three pts had grade 2 @entity1295 and @entity448 and one pt had grade 2 @entity16 . CONCLUSION: Our regimen offers an excellent palliative treatment with minimal @entity137 for elderly pts with comorbidities or pts with poor PS. Sponsored by GlaxoSmithKline. [Table: see text].
